Redx Pharma gets $9m as AstraZeneca initiates AZD5055 phase 1 trial
UK-based biotech company Redx Pharma said that it has received a milestone payment of $9 million from AstraZeneca following the initiation of a phase 1 clinical trial of AZD5055 (RXC006). AZD5055 is a porcupine inhibitor, which is targeted at fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and others. Redx Pharma had out-licensed the porcupine […]